| Original language | English (US) |
|---|---|
| Pages (from-to) | 336-337 |
| Number of pages | 2 |
| Journal | Movement Disorders Clinical Practice |
| Volume | 6 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 2019 |
ASJC Scopus subject areas
- Clinical Neurology
- Neurology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Movement Disorders Clinical Practice, Vol. 6, No. 4, 04.2019, p. 336-337.
Research output: Contribution to journal › Letter › peer-review
TY - JOUR
T1 - Reply to
T2 - DUOPA® is an Excellent Alternative Treatment but with Some Caveats
AU - Burack, Michelle
AU - Aldred, Jason
AU - Zadikoff, Cindy
AU - Vanagunas, Arvydas
AU - Klos, Kevin
AU - Bilir, Bahri
AU - Fernandez, Hubert H.
AU - Standaert, David G.
N1 - Funding Information: Ethical Compliance Statement: The authors confirm that the approval of an institutional review board was not required for this work. We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. Funding Sources and Conflicts of Interest: M.B. has no relevant disclosures to report. J.A. has served as a consultant for AbbVie and has participated in AbbVie speakers’ bureaus. C.Z. has served as an advisor and received honoraria and educational grants from AbbVie. A.V. has served as a consultant for AbbVie and is a member of the Pharmacy and Therapeutics Committee for CVS/Caremark. K.K. has served as a consultant for AbbVie and has participated in AbbVie speakers’ bureaus. B.B. has no disclosures to report. H.H.F. has served as a consult for and has received research grants from AbbVie. D.G.S has served as a consultant to AbbVie Financial Disclosures for the previous 12 months: M.B. owns stock in Novartis, and has received scientific advisory honoraria from Lundbeck and speaker’s honoraria from Onandaga County Department of Adult and Long Term Care Services. J.A. has received research support from US World Med, AbbVie, National Institutes of Neurological Disorders and Stroke, National Parkinson Foundation, Biogen, Boehringer Ingelheim, Lundbeck, and Impax, and has been a speaker for US World Meds, TEVA, Lundbeck, and AbbVie. C.Z. has served as an advisor for AbbVie, Teva, Cynapsus, Lundbeck, UCB, and Merz; has received honoraria from Teva, UCB, US World Meds, Cynapsus, AbbVie, Acadia, Lundbeck, and Merz. She has also received educational grants from AbbVie, Teva, and Allergan. A.V.: has no disclosures to report. K.K. has received research support and funding from US World Meds, Pfizer Pharmaceuticals, Neuroderm Ltd, Merz, Cynapsus Therapeutics Inc., Solstice Neurosciences LLC, Intec Pharma, Ltd., Adamas Pharmaceuticals, Biotie Therapeutics, Inc., and AUSPEX Pharmaceuticals. He has served as an advisor and received honoraria on the speaker bureau for AbbVie and UCB pharmaceuticals. B.B. has no disclosures to report. H.H.F. has received research support from AbbVie, Acadia, Teva, Biotie/Acorda Therapeutics, Civitas, Kyowa/Prostrakan, Michael J. Fox Foundation, Movement Disorders Society, NIH/NINDS, Parkinson Study Group, Rhythm, and Synosia, and has received a stipend from the International Parkinson and Movement Disorders Society for serving as Medical Editor of the MDS website. He has served as a consultant for Biogen, GE Health Care, Inventiv, Kyowa Hakko Kirin, Lundbeck, Medscape, Merz Pharmaceuticals, Voyager, Sunovion, and Pfizer Pharmaceuticals, and has received honoraria from Prime Education Inc., International Parkinson and Movement Disorders Society, Carling Communications, and Medscape. He has received royalties for publications from Demos Publishing. D.S. is a member of the faculty of the University of Alabama at Birmingham and is supported by endowment and University funds. He is an investigator in studies funded by AbbVie, Inc., the American Parkinson Disease Association, Michael J. Fox Foundation for Parkinson Research, Alabama Department of Commerce, and NIH grants P01NS087997, P20NS087997, R25NS079188, P2CHD086851, and P30NS047466. He has a clinical practice and is compensated for these activities through the University of Alabama Health Services Foundation. In addition, since January 1, 2016 he has served as a consultant for or received honoraria from, Serina Therapeutics, AbbVie, Voyager Therapeutics, Michael J. Fox Foundation for Parkinson Research, The International Parkinson Disease and Movement Disorder Society, the National Institutes of Health, The American Institute for Biological Sciences, Rush University, Huntsville Hospital, UCSD, Voyager Therapeutics, and he has received royalties for publications from McGraw Hill, Inc.
PY - 2019/4
Y1 - 2019/4
UR - http://www.scopus.com/inward/record.url?scp=85063573022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85063573022&partnerID=8YFLogxK
U2 - 10.1002/mdc3.12738
DO - 10.1002/mdc3.12738
M3 - Letter
C2 - 31061847
AN - SCOPUS:85063573022
SN - 2330-1619
VL - 6
SP - 336
EP - 337
JO - Movement Disorders Clinical Practice
JF - Movement Disorders Clinical Practice
IS - 4
ER -